Transpharmation Logo
  • Contact Us

Models & Assays

Elevated Zero Maze

The Elevated Zero Maze (EZM) is a widely used test to assess anxiety-like behavior in rodents, which is based on their conflicting innate tendencies: exploring a new environment and avoiding elevated and open spaces. The EZM test, which is a modification of the Elevated Plus Maze (EPM) test, offers increased motivation for animals to explore the open and brightened areas, due to the more continuous nature of the apparatus and the absence of the central square. The EZM test demonstrates high predictive validity in assessing the effectiveness of anxiolytic agents, resulting in an increased time spent by animal in the open arms.

Internal studies conducted by the Transpharmation research team on male BALB/c mice (10-12 weeks old) have confirmed the efficacy of diazepam (1 mg/kg, s.c.) as an anxiolytic agent in the EZM test. Acute diazepam administration reduced anxiety-like behavior in mice, as evidenced by increased locomotor activity and time spent in the open compartments.


  1. Tucker, Laura B., and Joseph T. McCabe. "Behavior of male and female C57BL/6J mice is more consistent with repeated trials in the elevated zero maze than in the elevated plus maze." Frontiers in behavioral neuroscience 11 (2017): 13.
  2. Kulkarni SK, Singh K, Bishnoi M. Elevated zero maze: a paradigm to evaluate antianxiety effects of drugs. Methods Find Exp Clin Pharmacol. 2007;29(5):343-348.

Company

  • Our Team
  • Publications
  • News
  • Careers
  • Animal Welfare
  • Privacy Policy
  • Accessibility Policy
  • Cookies Policy

Services

  • Abuse Liability / Substance Use Disorders
  • Alzheimer's Disease
  • Bioanalytical Studies
  • CNS Drug Disposition
  • Cognitive Assessment
  • Depression/Anxiety
  • Dermatology
  • EEG
  • Epilepsy
  • Essential Tremor
  • Imaging
  • Inflammatory Pain
  • Inflammation
  • Medical Cannabis
  • Metabolic Disorders
  • Migraine
  • Molecular Biomarkers
  • Multiple Sclerosis
  • Neuropathic Pain
  • Operant Platform
  • Osteoarthritis
  • Parkinson's Disease
  • PK/PD Studies
  • PK-Bridge
  • Psychedelics
  • PXB Mouse Studies
  • Safety Studies
  • Schizophrenia
  • Veterinary Research
North America
1-548-538-2371
Europe
+44 (0)130 440 3165
Contact us

© 2024 Transpharmation™. All Rights Reserved.
Sitemap
LinkedIn account
Youtube account